VMD Stock Recent News

Viemed Healthcare, Inc. (NASDAQ:VMD ) Q1 2025 Earnings Conference Call May 8, 2025 11:00 AM ET Company Participants Casey Hoyt – Chief Executive Officer Trae Fitzgerald – Chief Financial Officer Todd Zehnder – Chief Operating Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Ryan Langston – TD Cowen Andrew Rem – Odinson Partners Operator Good day, ladies and gentlemen, and welcome to the Viemed Healthcare First Quarter 2025 Earnings Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Trae Fitzgerald, CFO.

LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025.

LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment (“Lehan”), a healthcare company offering home medical equipment with specialties in respiratory care and women's health.

DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particul

LAFAYETTE, La., April 22, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, today announced that it will host its First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025, at 11:00 a.m. EDT.

Viemed Healthcare's stock has declined recently, but bullish EPS revisions and strong growth projections make it an attractive buy near its long-term bottom. The company projects significant revenue and EBITDA growth for 2025, with EPS expected to rise by 42.86% in 2025 and 52.5% in 2026. Viemed's valuation remains attractive, with positive cash flow and rising equity, despite the stock's recent bearish trend.

Viemed Healthcare, Inc. (NASDAQ:VMD ) Q4 2024 Earnings Conference Call March 11, 2025 11:00 AM ET Company Participants Todd Zehnder - COO Trae Fitzgerald - CFO Casey Hoyt - CEO Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Andrew Rem - Odinson Partners Operator Greetings, and welcome to the Viemed Healthcare Year-End 2024 Earnings Call. At this time all participants are in a listen-only mode.

LAFAYETTE, La., March 10, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months and year ended December 31, 2024, and issued its guidance for the full year ending December 31, 2025.

Upgraded Viemed Healthcare to 'Buy' due to bullish technicals, strong Q2 earnings, and promising growth trends in ventilator and sleep businesses. Bullish MACD crossover and strong buying volume signal potential for sustained share price increase. Q2 revenue hit $55 million, with notable organic growth and successful sales force restructuring driving performance.

LAFAYETTE, La., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three and six months ended June 30, 2024.